Sanofi gets binding bids for consumer unit
Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and ...
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.
NEW YORK (Reuters) - Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on ...
EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
21h
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback